Patient Education & FAQ

Twenty patient questions about T-cell lymphoma: diagnosis, treatment and daily decisions

It is enough to begin contacting a specialist, but usually not to define the entire treatment plan. The team needs to establish whether the process is mature or precursor disease, its principal sites and any remaining classification questions. Ask for the complete entity and the degree of diagnostic certainty, followed by an explanation of which additional findings could change the recommendation. ESMO–EHA addresses distinct entities because treatment depends on that distinction. If a clinical problem needs urgent attention, the physician should coordinate it alongside the investigation rather than leaving the patient to choose between waiting and starting therapy alone. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

  • Review checks whether morphology, marker findings and the clinical picture support the same conclusion. It does not necessarily mean the original work was wrong. T-cell lymphomas can resemble reactive conditions or other malignancies, and a new treatment question may require further interpretation. Providing the complete report and the materials requested by the receiving laboratory can help avoid unnecessary repeat sampling, although another biopsy may still be needed. CAP emphasizes appropriate tissue and integrated ancillary tests; a photograph of the final diagnostic sentence cannot provide the same information. CAP/ASCP: Laboratory Workup of Lymphoma in Adults guideline
  • Not necessarily. Much established CAR-T experience concerns B-cell cancers. T-cell lymphoma research involves different targets and biological challenges. An early TRBC1-directed study concerns patients meeting its particular criteria; its findings do not establish applicability to all PTCL or routine commercial availability in China. Ask about the target, eligible disease, trial phase and registration number, and let the study team assess eligibility. The broad phrase cellular therapy in an advertisement does not answer those questions or establish that the intervention is suitable. Cwynarski et al.: TRBC1-CAR T-cell therapy in PTCL, phase 1/2 report
  • Bring complete pathology and consultation reports, key original imaging, a dated record of each treatment line and response, recent laboratory results, current prescriptions and major adverse events. After transplantation, add the dedicated summary and immunosuppressive plan. Write down the questions that matter most to the patient. NCI's follow-up information explains the value of an accurate treatment summary and clear care responsibilities. The package can be simple, but it should be readable and traceable to dates and original documents. Mark an unknown item for verification rather than filling it with a confident estimate from memory. NCI: Follow-Up Medical Care after Cancer Treatment

Quick answer

It is enough to begin contacting a specialist, but usually not to define the entire treatment plan. The team needs to establish whether the process is mature or precursor disease, its principal sites and any remaining classification questions. Ask for the complete entity and the degree of diagnostic certainty, followed by an explanation of which additional findings could change the recommendation. ESMO–EHA addresses distinct entities because treatment depends on that distinction. If a clinical problem needs urgent attention, the physician should coordinate it alongside the investigation rather than leaving the patient to choose between waiting and starting therapy alone. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

Full guide

1. Is a report saying T-cell lymphoma enough to choose treatment?

It is enough to begin contacting a specialist, but usually not to define the entire treatment plan. The team needs to establish whether the process is mature or precursor disease, its principal sites and any remaining classification questions. Ask for the complete entity and the degree of diagnostic certainty, followed by an explanation of which additional findings could change the recommendation. ESMO–EHA addresses distinct entities because treatment depends on that distinction. If a clinical problem needs urgent attention, the physician should coordinate it alongside the investigation rather than leaving the patient to choose between waiting and starting therapy alone. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

2. Why does another hospital want to review a biopsy already performed?

Review checks whether morphology, marker findings and the clinical picture support the same conclusion. It does not necessarily mean the original work was wrong. T-cell lymphomas can resemble reactive conditions or other malignancies, and a new treatment question may require further interpretation. Providing the complete report and the materials requested by the receiving laboratory can help avoid unnecessary repeat sampling, although another biopsy may still be needed. CAP emphasizes appropriate tissue and integrated ancillary tests; a photograph of the final diagnostic sentence cannot provide the same information. CAP/ASCP: Laboratory Workup of Lymphoma in Adults guideline

3. Can a positive CD30 or ALK result determine the medicine by itself?

These results can be important, but their meaning depends on the final entity. CD30 has different implications across diseases, and ALK requires interpretation with morphology and other findings. Ask which classification the result supports, whether the proposed treatment evidence concerns that entity and what the regional indication permits. The International Consensus Classification uses multiple features to identify disease. A patient does not need to turn every positive marker into a search for a matching drug, and an isolated result is not a personal prescription. Campo et al.: International Consensus Classification of Mature Lymphoid Neoplasms, 2022

4. Does a variant on tumor testing mean my children will inherit the disease?

An acquired change in tumor cells is different from an inherited germline finding. The specimen, purpose of the test and any recommendation for genetic counseling need professional interpretation. A gene name alone should not lead a family to conclude that an inherited disorder has been diagnosed. Conversely, a negative tumor panel does not settle every question about familial risk. NCI explains that cancer biomarker testing has a particular role and may produce uncertain or limited findings. If inherited risk is a concern, an appropriate genetics assessment should address it separately. NCI: Biomarker Testing for Cancer Treatment

5. If PET shows little disease, do marrow results still matter?

Yes. PET and marrow sampling can provide different information, and a negative finding in one does not automatically cancel the other. The 2025 CHEMO-T substudy reported discordance in PTCL, so rules developed for particular other lymphoma settings should not simply be transferred. The clinician considers the entity, blood counts, baseline findings and reason for assessment when deciding on marrow evaluation. Bring both sets of results and ask for an explanation of their relationship rather than selecting whichever report feels more reassuring. CHEMO-T investigators: PET/CT substudy in peripheral T-cell lymphoma, 2025

6. Does an advanced stage mean treatment has no purpose?

Stage describes distribution, but does not by itself determine the treatment objective or individual outcome. Functional health, subtype, responsiveness and acceptable risk also influence decisions. Advanced disease does not make every treatment pointless, just as limited stage cannot guarantee an uncomplicated course. Ask whether the present aim is remission, durable control or relief of a particular problem, and how it will be assessed. NCI's prognosis information distinguishes population statistics from an individual's experience. An online survival figure cannot replace a discussion informed by the person's actual circumstances. NCI: Understanding Cancer Prognosis

7. Why was another patient offered a different first regimen?

The difference may reflect entity, CD30 expression, prior treatment, fitness or organ function. A patient with non-ALCL nodal PTCL should not assume that hearing about ECHELON-2 establishes an identical choice for everyone; the population and strength of evidence require careful interpretation. Ask the physician what supports the selected regimen and why an alternative is less suitable or less preferred. First compare the clinical settings. The number of medicines, whether their names sound newer, or another patient's tolerance does not independently establish which regimen is appropriate. Horwitz et al.: ECHELON-2 five-year results d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

8. Does US approval mean a drug can be used for the same purpose in China?

That cannot be assumed. Authorized diseases, previous-treatment requirements and supply may differ by jurisdiction. China's national guidance distinguishes domestic indications from some overseas uses. Confirm the generic name, full diagnosis, prior therapy and proposed use with the clinician and pharmacy. A combination or maintenance indication in another lymphoma should not be transferred to PTCL. A publication reporting activity, a regulatory authorization and the hospital's ability to prescribe the medicine are separate pieces of information, each of which may need verification. 中国国家卫生健康委：《新型抗肿瘤药物临床应用指导原则（2025年版）》，2026-01-26发布

9. Must everyone who reaches remission have a transplant?

No single answer covers all entities and clinical settings. The discussion includes relapse risk, depth of response, fitness and treatment goals. Autologous and allogeneic approaches are also different: one uses the patient's own cells for hematopoietic support, while the other introduces donor immune effects and corresponding risks. EBMT discusses transplantation by disease and status rather than requiring it for every first remission. Ask why it is proposed, what alternatives exist and how follow-up would work without it. Availability of a bed should not determine the clinical indication. Hübel et al.: Other B- and T-Aggressive Lymphomas, EBMT Handbook 2024

10. After relapse, are trial medicines the only option?

A trial may be worth considering, but is not universally the only pathway. The team needs to confirm what has recurred, review the activity and toxicity of previous medicines, and consider whether other systemic therapy, local treatment or transplantation is applicable. NCI's PTCL information describes several relapse settings, but each option still requires entity-specific judgement. If research is considered, understand care after unsuccessful screening or discontinuation of the study treatment. Ask for a discussion of options relevant to the current records rather than only a list of research titles. NCI PDQ: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment

11. Does the availability of CAR-T mean it can treat my T-cell lymphoma?

Not necessarily. Much established CAR-T experience concerns B-cell cancers. T-cell lymphoma research involves different targets and biological challenges. An early TRBC1-directed study concerns patients meeting its particular criteria; its findings do not establish applicability to all PTCL or routine commercial availability in China. Ask about the target, eligible disease, trial phase and registration number, and let the study team assess eligibility. The broad phrase cellular therapy in an advertisement does not answer those questions or establish that the intervention is suitable. Cwynarski et al.: TRBC1-CAR T-cell therapy in PTCL, phase 1/2 report

12. Does registering interest in a trial guarantee access to the new medicine?

An enquiry or registration begins contact or screening. Eligibility may depend on tissue confirmation, laboratory findings, previous therapies and protocol-defined timing. The design may involve allocation, dose cohorts or other conditions. Consent information should explain purpose, risks, expenses and withdrawal, with an opportunity to ask questions before signing. Do not stop the existing regimen independently to try to qualify. NCI's consent material describes an informed and voluntary process; an intermediary's assurance cannot replace confirmation by the research service or the actual study documents. NCI: Understanding Cancer Research Consent Forms

13. Can fever after chemotherapy be watched overnight after taking a fever reducer?

Follow the treatment team's immediate contact instructions, particularly during neutropenia or substantial immunosuppression. An antipyretic may conceal symptoms, and a falling temperature does not establish that an infection is safe. Shaking chills, breathlessness, confusion or marked weakness warrant prompt emergency assessment. Tell the receiving staff the latest treatment date, current medicines and allergies. NCI emphasizes the need for timely response to possible infection. Waiting for the next clinic session or for a clinician in another time zone to become available can delay needed care. NCI: Infection and Neutropenia during Cancer Treatment

14. Should I report numb hands or feet if I can still tolerate them?

Yes. Describe whether buttons, cups, walking or balance are affected, when the change started and whether it is progressing. Some treatments can injure peripheral nerves, and the clinician may need to examine the patient and modify the plan before function deteriorates substantially. NCI advises reporting these changes and taking precautions against falls and burns. Do not reduce treatment on your own, but do not assume that a shrinking lymphoma requires accepting any degree of nerve symptoms. Early detail helps the team balance continued treatment with safety. NCI: Nerve Problems and Cancer Treatment

15. If mouth pain prevents eating, are nutritional supplements enough?

The cause and consequences need assessment, including mucosal injury, infection and dehydration. Supplements cannot replace that evaluation. Contact the team when drinking or swallowing essential medicines becomes difficult, or when fever accompanies mouth problems. Soft food at a comfortable temperature may help, and cleaning methods should follow nursing advice. With pralatrexate, confirm the prescribed folic acid and vitamin B12 support and monitoring plan. Its label addresses mucositis management; an arbitrary multivitamin is not an equivalent substitute for the treatment-specific prescription. NCI: Mouth and Throat Problems during Cancer Treatment DailyMed: FOLOTYN pralatrexate prescribing information

16. Is long-term maintenance medicine always needed after the main course?

The answer depends on disease and evidence. Some cutaneous T-cell lymphoma strategies involve continuing control, while maintenance after initial systemic-PTCL treatment cannot be generalized. The 2026 JACKPOT26 report investigated golidocitinib maintenance; it does not establish one standard indication for everyone who reaches remission. Ask the clinician to document the purpose, evidence, monitoring and stopping conditions for continued treatment. Neither another disease's prescribing provision nor a single-arm research schedule should become the reason for indefinite personal treatment without the relevant clinical assessment. NCI PDQ: Mycosis Fungoides and Sézary Syndrome Treatment Wei et al.: JACKPOT26 maintenance study, Blood Cancer Journal 2026

17. How often should I have PET after returning home to feel safe?

Reassurance should not depend solely on adding scans. ESMO–EHA does not recommend routine PET-CT or diagnostic CT surveillance for PTCL in complete remission. Follow-up incorporates history, examination and investigations prompted by the clinical situation. Report a new lump, persistent fever or another concerning change early so the clinician can decide about imaging or tissue. Transplantation, residual disease and ongoing therapy can create different requirements. Repeated self-arranged scans at several hospitals may create difficult findings without making the care more dependable. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

18. Can a published package price be used to budget for treatment in China?

A total advertised online may concern an initial consultation or a single administration rather than the patient's subtype and treatment stage. Ask the hospital for a staged estimate covering medicines, investigations, supportive care, admission and any conditional transplant pathway. Identify what remains undecided. Reimbursement and commercial-insurance catalogues also do not establish identical coverage for an overseas visitor. The current NHSA catalogue has payment-scope provisions, while personal settlement requires confirmation from the hospital and payer. An unsupported fixed renminbi range can create a false expectation for the family. 国家医保局：2025年医保药品目录及商保创新药目录通知，2026-01-01执行

19. Can I fly home as soon as I am discharged?

Discharge means that appropriate care can currently continue outside the inpatient unit. It does not by itself establish fitness for long-distance travel. Blood counts, infection, oxygen needs, mobility, immunosuppression and care available at the destination may matter. CDC's immunocompromised-traveler guidance supports individual assessment; after transplantation, coordination with the receiving clinician is particularly important. Confirm airline assistance requirements, medicines carried with the patient and emergency contacts before fixing the return. A ticket date should not replace medical evaluation or lead to interruption of necessary monitoring. CDC Yellow Book 2026: Immunocompromised Travelers

20. What should I bring to make the next medical consultation useful?

Bring complete pathology and consultation reports, key original imaging, a dated record of each treatment line and response, recent laboratory results, current prescriptions and major adverse events. After transplantation, add the dedicated summary and immunosuppressive plan. Write down the questions that matter most to the patient. NCI's follow-up information explains the value of an accurate treatment summary and clear care responsibilities. The package can be simple, but it should be readable and traceable to dates and original documents. Mark an unknown item for verification rather than filling it with a confident estimate from memory. NCI: Follow-Up Medical Care after Cancer Treatment

References

Related guides